Previous 10 | Next 10 |
2024-03-26 16:12:23 ET More on Biora Therapeutics Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Financial information for Biora Therapeutics ...
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. T...
2024-03-11 08:50:16 ET More on Biora Therapeutics Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Financial information for Biora Therapeutics Read the full article on Seeking Alpha For further...
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora’s net debt SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech ...
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery,...
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on...
SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8...
SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance on anticipated milestones during 2024. “In 2023, we completed the transformation of the company, focusin...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...